Investors
CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; XETRA-DAX: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.
CLINUVEL’s Annual Results Appendix 4E – Full Yearly Report for the Year Ended 30 June 2022 is now available online.
On 19 September 2022 CLINUVEL announced its fifth Strategic Update – click here to explore the microsite.
Latest News
Share Price
CLINUVEL is listed on the Australian
Securities Exchange under the ticker code CUV.
Share Price Graph
Announcements Calendar 2021
| Mandatory Announcements to the Australian Securities Exchange | Due Date |
|---|---|
| Appendix 4C - Quarterly Cash Flow | 31 January 2022 |
| Appendix 4D - Half Yearly Report | 28 February 2022 |
| Appendix 4C - Quarterly Cash Flow | 28 April 2022 |
| Appendix 4C - Quarterly Cash Flow | 29 July 2022 |
| Appendix 4E - Full Year Results | 31 August 2022 |
| Appendix 4C - Quarterly Cash Flow | 31 October 2022 |
Except for scheduled announcements to the Australian Securities Exchange, the timing of announcements is subject to change by the Company.
CLINUVEL online
Click the buttons to view our social media channels
and see what’s happening around the Company.
Company Snapshot
CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; XETRA-DAX: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.
CLINUVEL’s lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel and Australia as the world’s first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA.
SCENESSE®, PRÉNUMBRA®, and NEURACTHEL® are registered trademarks of CLINUVEL.
| Fact | ASX Listed 2001 Shares on Issue | 49,410,338 |
|---|---|---|
| Conditional performance rights | 1,784,583 | |
| Locations | Melbourne, Australia | Company headquarters |
| Zug, Switzerland | Swiss operational office | |
| Dublin, Ireland | EU operational office | |
| Monaco | Monaco operational office | |
| Leatherhead, UK | UK operational office | |
| Singapore | VALLAURIX Research, Development & Innovation Centre | |
| Burlingame, US | US operational office | |
| www.clinuvel.com | ||
| Stock Listings | ASX | CUV |
| Xetra-DAX | UR9 | |
| Level 1 ADR | CLVLY | |
| Key Financial Statistics FY June 2022 |
Total revenues | A$67.0m |
| Net profit | A$20.9m | |
| Net cash increase | A$37.9m | |
| Cash | A$121.5m | |
| Total assets | A$143.9m | |
| Equity | A$125.6m | |
| Products | SCENESSE® (afamelanotide 16mg implant) |
|
CUV9900 |
||
Parvysmelanotide (VLRX001) |
||
PRÉNUMBRA® |
||
NEURACTHEL® (ACTH) |
||
| People | Willem Blijdorp | Non-Executive Chair |
| Dr Philippe Wolgen | CEO, Managing Director | |
| Brenda Shanahan | Non-Executive Director | |
| Dr Karen Agersborg | Non-Executive Director | |
| Susan Smith | Non-Executive Director | |
| Professor Jeffrey V. Rosenfeld | Non-Executive Director | |
| Professor Sir Andrew Likierman | Non-Executive Director | |
| Darren Keamy | CFO, Company Secretary | |
| Dr Dennis Wright | Chief Scientific Officer | |
| Lachlan Hay | Director of Global Operations | |
Financial
overview
CLINUVEL’s end of financial year is 30 June.
5 Year Financial Summary
|
PROFIT & LOSS |
2022 |
2021 |
2020 |
2019 |
2018 |
2017 |
||
|
Revenues |
A$m |
67.0 |
48.5 |
33.9 |
32.5 |
26.2 |
17.2 |
|
|
Expenses |
A$m |
32.7 |
22.7 |
22.4 |
14.4 |
13.3 |
10.1 |
|
|
Net Profit / (Loss) |
A$m |
20.9 |
24.7 |
15.1 |
18.1 |
13.2 |
7.1 |
|
|
BALANCE SHEET |
2022 |
2021 |
2020 |
2019 |
2018 |
2017 |
||
|
Cash & Cash equivalents |
A$m |
121.5 |
82.7 |
66.7 |
54.3 |
36.2 |
23.8 |
|
|
Total Assets |
A$m |
143.9 |
108.6 |
81.5 |
62.3 |
42.9 |
28.6 |
|
|
Total Liabilities |
A$m |
18.4 |
9.8 |
9.5 |
5.2 |
3.5 |
3.1 |
|
|
Equity |
A$m |
125.6 |
98.7 |
72.1 |
57.2 |
39.4 |
25.4 |
|
|
CASH FLOW |
2022 |
2021 |
2020 |
2019 |
2018 |
2017 |
||
|
Cashflow (used in ) operating activities |
A$m |
39.9 |
19.3 |
14.2 |
18.4 |
11.7 |
9.9 |
|
|
Net increase in cash held |
A$m |
37.9 |
16.9 |
11.8 |
17.2 |
11.6 |
9.9 |
|
|
KEY VARIABLES |
2022 |
2021 |
2020 |
2019 |
2018 |
2017 |
||
|
Basic Earnings per Share |
Cents |
42.3 |
50.0 |
30.6 |
37.6 |
27.7 |
14.9 |
|
|
Net Tangible Assets Backing |
A$ per share |
2.5 |
1.9 |
1.4 |
1.2 |
0.8 |
0.5 |
|
|
Return on Equity |
% |
17 |
25 |
21 |
32 |
34 |
28.0 |
|
Some figures in the table may vary slightly to CLINUVEL’s reporting due to rounding.
Click here to see our Annual Reports.
Please refer to the Announcements Calendar for planned financial releases.
CLINUVEL has raised over A$95.0 million since 2006 to fund its clinical programme for afamelonotide
Capital Raisings
* Represented at post-consolidated basis after capital re-organisation
November 2010 (10:1 Reverse Stock Split).
Shareholder
Information
ASX Shareholders
CLINUVEL maintains its ASX shareholder registry with Computershare. For all enquiries related to your shareholding, contact:
The Registrar
Computershare Investor Services Pty Limited
GPO Box 2975
Australia
(Aus) 1300 555 159
(International) +61 (0)3 9415 4062
Shareholders are able to access the company’s share registry with Computershare online and perform the following tasks:
View Your Security Holdings
-Account Details
-Balances
-Communication Details
Change your Shareholdings Records
Click here to go to the Computershare website.
American Depository Receipts holders
CLINUVEL’s stock is available as a Level I OTC-traded ADR sponsored by the Bank of New York Mellon with the symbol CLVLY.
For all enquiries related to ADR ownership, contact:
BNY Mellon Shareowner Services
P.O. Box 358516
Pittsburgh, PA 15252-8516
USA (USA) 1888 BNY ADRS or – 1888 269 2377 (toll free)
(International) +1 201 680 6825
Email: shrrelations@bnymellon.com
Website: www.adrbnymellon.com
Media Coverage
| AUTHOR | PUBLISHER | DATE | AUTHOR BIO | PUBLISHER PROFILE |
|---|---|---|---|---|
| David Koch & Nadine Blayney & Daniel Weiner | Ausbiz | 18 June 2020 23 April 2020 02 April 2020 | David Koch is a prominent financial journalist, co-host of a national television breakfast program, co-founder of ausbiz and host of The Call program. CLINUVEL has been interviewed by ausbiz co-anchors Nadine Blayney who has covered business and media since 2005, and Daniel Weiner who joined ausbiz after a career as a trader in global financial markets. | Ausbiz is a business and financial news, live streaming and on demand, service which commenced in March 2020. The Call is a daily program on ausbiz. |
| Kate O'Brien | The Motley Fool | 15 June 2020 | Kate O’Brien writes for The Motley Fool on consumer product, healthcare, finance, and legal matters and has worked as an analyst and consultant in the finance industry. Nick Sundich is an experienced financial journalist focused on corporate strategy and market trends. He writes predominately for Stockhead and holds Commerce and Arts degrees from University of Sydney. | The Motley Fool was established in 1993 and provides investment and financial advice to its large membership |
| Nick Sundich | Stockhead | 10 June 2020 23 April 2020 23 March 2020 | Nick Sundich is an experienced financial journalist focused on corporate strategy and market trends. He writes predominately for Stockhead and holds Commerce and Arts degrees from University of Sydney. | Stockhead Australia draws on a team of contributing journalists to report online daily on emerging small and micro listed stocks. It is owned by AG Media Investments |
| Jessica De Freitas | The Market Herald | 23 April 2020 | Jessica De Freitas has a digital marketing background with a Bachelor of Arts in communications and media. She writes on market news, specialising in real estate and consumer trends. | The Market Herald is a Perth based, leading source of Australian stock market news for self-directed investors. |
| Tim Boreham | The New Criterion | 02 April 2020 | Tim Boreham is a freelance business journalist with more than 30 years of experience writing on business for major publications, including The Australian. Sectors covered by Tim include banking, accounting, technology, property, and life sciences. Tim authors The New Criterion and Dr Boreham’s Crucible. | The New Criterion is published weekly online and focuses on small- to mid-capitalised stocks for Independent Investment Research which was established in 2004 and specialises in the analysis of high-quality commissioned research for brokers, family offices and fund managers. |
| Louise Weihart | Mergemarket | 31 March 2020 | Louise Weihart is an experienced journalist who understands business issues and has reported for Mergermarket for nearly 15 years. She is a graduate of the University of Witwatersrand. | Mergermarket is an Acuris company and distributes specialist M&A intelligence drawn from 500 correspondents worldwide to 175,000 subscribers interested in corporate strategy. |
| Will Boggs | M./D. Alert | 27 March 2020 | Will Boggs is a physician and freelance journalist based in the United States and covers life sciences for media outlets, including Reuters, Business Insider, HuffPost, The Globe and Mail, Scientific American, and M.D./alert. | M.D./alert is focused on informing physicians in all specialities about developments in healthcare. |
| Michael Bailey | The Australian Financial Review | 23 March 2020 | Michael Bailey writes on entrepreneurship and the arts and edits the Australian Financial Review’s Rich Lists. Michael has also been an editor in Fairfax Media. | The Australian Financial Review is an Australian business and finance newspaper which reports the latest news on business, investment, and politics. |
| Team Kalkine | Kalkine Media | 02 March 2020 | Team Kalkine is a team of journalists that review the latest developments across equity markets, debt markets, currency markets and commodity markets. | Kalkine Media is an independent equities research firm founded by Kunal Sawhney to provide recommendations to subscribers on stocks to buy, sell or hold. |
| Patrick McLoughlin | Youth Investment Group Australia | 28 February 2020 | Patrick McLoughlin has been a senior manager at Youth Investment Group Australia since August 2019 and holds business and law qualifications from the University of Technology Sydney. | Youth Investment Group Australia was founded by Tyger Fitzpatrick with the aim to educate young investors of the power of financial knowledge. |
| James Mickleboro | The Motley Fool | 26 February 2020 | James Mickleboro has contributed to The Motley Fool on business and finance since late 2015 and is also a Financial Analyst at ATI Wealth. James has written articles on Australian equities for The Motley Fool, Yahoo Finance and Seeking Alpha | The Motley Fool was established in 1993 and provides investment and financial advice to its large membership. |
Analyst coverage
CLINUVEL does not provide financial guidance on its earnings and financial performance. CLINUVEL does not endorse, confirm or express a view as to the accuracy of the analyst reports and the forecasts contained within them and does not make any representation that its earnings will fall within the range of the analyst’s forecasts. CLINUVEL does not induce, incentivise or remunerate analysts and journalists to publish and recommend CLINUVEL in their reports or mainstream media channels.
| Firm/Institution | Analyst | Date of Publication | Analyst Profile | Firm/Institution Profile |
|---|---|---|---|---|
| Bioshares | Mark Pachacz |
Latest coverage: No. 933, 3 February 2023 Initial coverage: No. 195, 01 December 2006 |
Mark Pachacz is co-founder (with David Blake (1962-2021)) and editor of Bioshares. He is a chemical engineer by training and a graduate of Monash University and the Securities Institute of Australia. | Bioshares is published by Blake Industry and Market Analysis Pty Ltd. Since 2000, Bioshares has cemented a reputation for highly knowledgeable, insightful, and independent coverage of life sciences, pharmaceutical and healthcare companies. |
| Jefferies Australia | David Stanton |
Latest coverage: 24 February 2023 Initial coverage: 13 October 2020 |
Dr Stanton is Head of Healthcare Equity Research Australia at Jefferies Australia Pty Ltd. He is a qualified Medical Specialist, holds a Master of Business Administration, and is an experienced and well regarded healthcare analyst. Dr Stanton has followed CLINUVEL’s development program since 2007. With Jefferies since September 2019, he has held senior analytical roles over 15 years with CSLA, Nomura, and ABN Amro. | Jefferies Financial Group Inc. (NYSE:JEF) is a leading international financial services company offering a range of investment banking, equities, fixed income, asset and wealth management products and services through subsidiaries worldwide, see https://www.jefferies.com. Healthcare is one of the firm’s 12 focus areas, with Jefferies maintaining a dedicated global healthcare research team which issues analyst coverage on over 270 companies in the sector. The annual Jefferies Global Healthcare Conference is recognised as the largest life sciences investment event in Europe. |
| Moelis Australia Securities | Sarah Mann |
Latest coverage: 26 February 2023 Initial coverage: 17 April 2019 |
Sarah Mann is a prominent analyst focused on the healthcare sector. With Moelis Australia since mid-2016, Sarah was previously an analyst at Credit Suisse. She holds a Bachelor of Liberal Studies from the University of Sydney with an undergraduate thesis in Immunology. At Moelis Australia, Sarah covers a number of companies across the healthcare and consumer sectors listed on the Australian Securities Exchange (ASX). | Moelis Australia Securities Ltd is a financial services group listed on the ASX, specialising in asset management, corporate advisory, and transaction services. They have a team of over 200, research 58 ASX-listed companies, manage funds of A$4.9bn and have advised on transactions worth over A$110bn since their launch in 2009. Moelis Australia commenced as a joint venture with the New York Securities Exchange (NYSE)-listed Moelis & Company, a leading global independent investment bank and Australian executives. |
| Wilsons Advisory | Shane Storey & Melissa Benson |
Latest Coverage: 27 Februar 2023 Initial coverage: 26 April 2021 |
Dr Storey has covered the healthcare sector at Wilsons for more than a decade and previously held positions in drug development, R&D project management, and venture capital. Dr Benson joined Wilsons in September 2020 after gaining experience in both industry and academia, primarily in clinical research and drug commercialisation roles. | Australian-based firm Wilsons offers services in private wealth management, corporate finance, research and investment strategy, and institutional sales. The group is focused on investment opportunities in emerging and mid-cap markets, and undertakes in-depth research on the healthcare, technology, financial services, consumer, food, and agriculture sectors. Wilsons currently covers 23 listed companies in Australia. |
Each research report is issued by a holder of an Australian Financial Services Licence. CLINUVEL does not distribute the original or copies of the analyst reports in observance of copyrights.
Annual Reports
Download CLINUVEL’s Annual Reports from previous years by clicking the links.
International Listings
Investor
enquiries
Investor enquiries
CLINUVEL sends regular email updates on its progress, as well as published announcements and analyst reports. You can subscribe to this database below.
Subscribing to CLINUVEL’s email updates service indicates your acceptance of our Privacy Policy.
Contact